On May 30, 2018 Perrigo Company plc (NYSE; TASE: PRGO) reported that Ron Winowiecki, Perrigo Chief Financial Officer, will present at the Jefferies 2018 Healthcare Conference at 8:30 AM EST on Tuesday, June 5, 2018 (Press release, Perrigo Company, MAY 30, 2018, View Source [SID1234527002]). Interested parties can access the presentation webcast at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 30, 2018 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, reported that the company will present at the Jefferies 2018 Global Healthcare Conference in New York (Press release, Corvus Pharmaceuticals, MAY 30, 2018, View Source;p=RssLanding&cat=news&id=2351343 [SID1234526947]). The presentation is scheduled for Wednesday, June 6, at 10:00 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via the conference website and from the investor relations section of the Corvus website.

On May 30, 2018 Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, and Nektar Therapeutics (Nasdaq: NKTR) reported a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar’s NKTR-214, a CD122-biased agonist, in combination with entinostat, Syndax’s oral, small molecule Class 1 specific HDAC inhibitor, in patients with metastatic melanoma who have previously progressed on treatment with an anti-PD-1 (programmed death receptor-1) agent (Press release, Syndax, MAY 30, 2018, View Source [SID1234526966]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Syndax and Nektar will collaborate on a study to evaluate the combination. The Phase 1b portion of the trial aims to establish safety and a recommended dose for the combination regimen and will be followed by a Phase 2 portion designed to assess efficacy, as defined by objective response rate and durability of response. Progression free survival and overall survival will also be evaluated. Correlative biomarker analyses that aim to identify patients with enhanced responses to the combination, including analyses exploring the potential of elevated levels of classical peripheral blood monocytes, will be incorporated. Syndax will be responsible for conducting the Phase 1b/2 trial and the agreement includes a provision where the parties may extend the collaboration to include a pivotal trial based on mutual interest.

"We are excited to be working with Nektar as we build upon our strategy of establishing clinical collaborations to test novel combinations of entinostat with leading edge immune therapies," said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. "Previous Phase 2 data with entinostat and high dose IL-2 in renal cell cancer1 and our promising preclinical data generated with NKTR-214, laid the scientific and clinical foundation for this collaboration. Working with Nektar allows us to increase the potential impact entinostat may have in the treatment of PD-1 refractory metastatic melanoma patients, and complements the exciting data we have seen when combining entinostat with KEYTRUDA in a similar population."

In preclinical testing, the results of which were recently presented at the 2018 American Association of Cancer Research Annual Meeting2, the combination of entinostat and NKTR-214 significantly inhibited tumor growth in tumor models of kidney and colon cancer. The anti-tumor activity of the combination was accompanied by a dramatic increase in the activation and cytotoxic activity of CD8+ T cells in the tumor, along with modulation of immune suppressor cells found in the tumor microenvironment.

"The combination of NKTR-214 and entinostat demonstrated a unique synergy in our preclinical models which warrants further study in the clinic," said Jonathan Zalevsky, Ph.D, Senior Vice President and Chief Scientific Officer of Nektar. "Importantly, we observed elevated levels of cytokine-positive tumor-infiltrating cytotoxic T cells following treatment with the combination. We believe this important preclinical finding could translate to improved tumor responses in patients who have become refractory to checkpoint inhibitors. We look forward to working with Syndax as this combination advances into the clinic."

Additional financial details and other terms of the agreement were not disclosed.

About Entinostat

Entinostat is a once-weekly, oral, small molecule, class I HDAC inhibitor currently being evaluated in a Phase 3 clinical trial in combination with exemestane for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer, an indication for which it has been granted Breakthrough Therapy Designation by the FDA. Entinostat has been shown to block the function of immune suppressive cells in the tumor microenvironment, and is being evaluated in combination with several approved PD-1/PD-L1 antagonists, including in ongoing Phase 1b/2 clinical trials combining entinostat with KEYTRUDA from Merck & Co., Inc. for non-small cell lung cancer, melanoma and colorectal cancer; with TECENTRIQ from Genentech, Inc. for triple negative breast cancer as well as advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer; and with BAVENCIO from Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

About NKTR-214

NKTR-214 is an experimental therapy designed to stimulate cancer-killing immune cells in the body by targeting CD122 specific receptors found on the surface of these immune cells, known as CD8+ effector T cells and Natural Killer (NK) cells. Growing these tumor-infiltrating lymphocytes (TILs) in vivo and replenishing the immune system is critically important as many patients battling cancer lack sufficient TIL populations to benefit from approved checkpoint inhibitor therapies. In preclinical studies, treatment with NKTR-214 resulted in a rapid expansion of these cells and mobilization into the tumor micro-environment.1,2 NKTR-214 has an antibody-like dosing regimen similar to the existing checkpoint inhibitor class of approved medicines.

On May 30, 2018 Array BioPharma Inc. (Nasdaq:ARRY) reported that its Chief Executive Officer, Ron Squarer, will speak at the Jefferies 2018 Global Healthcare Conference in New York (Press release, Array BioPharma, MAY 30, 2018, View Source [SID1234527438]). The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event:

Jefferies 2018 Global Healthcare Conference

Presenter:

Ron Squarer, Chief Executive Officer, Array BioPharma

Date:

Wednesday, June 6, 2018

Time:

2 p.m. Eastern Time

Webcast:

View Source

On May 30, 2018 In a few days’ time, the ASCO (Free ASCO Whitepaper) Annual Meeting will take place in Chicago, USA (1-5 June 2018) (Press release, EORTC, MAY 30, 2018, View Source [SID1234526948]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This year’s theme "Delivering discoveries: expanding the reach of precision medicine" focuses on making precision medicine a reality by driving progress and expanding its reach so that every patient can have the opportunity to benefit," Dr. Bruce Johnson, ASCO (Free ASCO Whitepaper) President.

EORTC reported it will present the results of several studies:

Oral presentations
Fifteen-year results of the randomised EORTC trial 22922/10925 investigating internal mammary and medial supraclavicular (IM-MS) lymph node irradiation in stage I-III breast cancer. (Abstract 504)
Oral Abstract Session: Breast Cancer – Local/Regional/Adjuvant

Time: Monday, June 4, 2018, 8:00 AM – 11:00 AM

Authors: Philip Poortmans, Sandra Collette, Henk Struikmans, Karin De Winter, Erik Van Limbergen, Carine Kirkove, Volker Budach, Karine Peignaux-Casasnovas, Ernest Vonk, Desiree van den Bongard, Sofia Rivera, Daniel Zips, Geertjan Van Tienhoven, Matthias Guckenberger, Roxolyana Abdah-Bortnyak, Alain Fourquet, Harry G. M. Bartelink

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6. (Abstract 3500)
Oral abstract Session: Gastrointestinal Cancer

Time: Tuesday, June 5, 2018, 9:45 AM – 12:45 PM

Authors: Hans-Joachim Schmoll, Karin Haustermans, Timothy Jay Price, Bernard Nordlinger, Ralf Hofheinz, Jean-Francois Daisne, Jaak Janssens, Baruch Brenner, Peter Schmidt, Hans Reinel, Stephan Hollerbach, Karel Caca, Florian W.B. Fauth, Carla Hannig, John Raymond Zalcberg, Niall C. Tebbutt, Murielle E. Mauer, Sandrine Marreaud, Manfred P. Lutz, Eric Van Cutsem

Poster presentations
Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE. (Abstract 11540)
Poster Session: Sarcoma

Time: Saturday, June 2, 2018 – 8:00 – 11:30 AM

Authors: Patrick Schöffski, Agnieszka Wozniak, Bernd Kasper, Steinar Aamdal, Michael Gordon Leahy, Piotr Rutkowski, Sebastian Bauer, Hans Gelderblom, Antoine Italiano, Lars H Lindner, Ivo M. Hennig, Sandra J. Strauss, Branko Zakotnik, Alan Anthoney, Birgit Geoerger, Jean-Yves Blay, Peter Reichardt, Winette TA van der Graaf, Sandrine Marreaud, Silvia Stacchiotti

Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). (Abstract 11574)
Poster Session: Sarcoma

Time: Saturday, June 2, 2018 – 8:00 – 11:30 AM

Authors: Lorenzo D’Ambrosio, Nathan Touati, Jean-Yves Blay, Giovanni Grignani, Ronan Flippot, Anna Malgorzata Czarnecka, Sophie Piperno-Neumann, Javier Martin Broto, Roberta Sanfilippo, Daniela Katz, Florence Duffaud, Bruno Vincenzi, Bernd Kasper, Daniel P. Stark, Filomena Mazzeo, Armin Tuchscherer, Saskia Litiere, Ward Sents, Hans Gelderblom, Alessandro Gronchi, on behalf of the EORTC STBSG

BEST OF: A phase III study assessing the best of radiotherapy (Intensity Modulated RadioTherapy, IMRT) compared to the best of surgery (Trans-Oral Surgery, TOS) in patients with T1-T2, N0 oropharyngeal squamous cell carcinoma (OPSCC). (Abstract TPS6098)
Poster Session: Head and Neck Cancer

Time: Saturday, June 2, 2018, 1:15 – 4:45 PM

Authors: Christian Simon, Carmela Aves Caballero, Catherine Fortpied, Mererid Evans, Petri Koivunen, Jean-Jacques Stelmes, Maria Urbanowicz, Jean Bourhis, Frank Zimmermann, Jens Peter Klussmann, Andreas Dietz, Giuseppe Spriano, C. Rene Leemans, Susanne Singer, Inge Tinhofer, Joanne Patterson, Silvana Quaglini, Keith Hunter, Vincent Gregoire

Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578). (Abstract TPS6099)
Poster Session: Head and Neck Cancer

Time: Saturday, June 2, 2018, 1:15 – 4:45 PM

Authors: Laura Locati, Carmela Aves Caballero, Catherine Fortpied, Federica Perrone, Pasquale Quattrone, Kevin Harrington, Vincent Gregoire, Lisa F. Licitra

EORTC 1559-HNCG: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)—"UPSTREAM". (Abstract TPS6095)
Poster Session: Head and Neck Cancer

Time: Saturday, June 2, 2018, 1:15 – 4:45 PM

Authors: Rachel Galot, Lisa F. Licitra, Christophe Le Tourneau, Joel Guigay, Inge Tinhofer, Anthony Hee Kong, Carmela Aves Caballero, Catherine Fortpied, Anne-Sophie Govaerts, Dominiek Staelens, Tiana Raveloarivahy, Jean-Francois Laes, Jean-Luc Re Canon, Stéphanie Henry, Esma Saada-Bouzid, Jean-Pascal H. Machiels

Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406). (Abstract 2023)
Poster Session: Central Nervous, System Tumors

Time: Saturday, June 2, 2018, 1:15 PM – 4:45 PM

Authors: Martin J. Van Den Bent, Pim French, Marica Eoli, Juan M. Sepúlveda, Anna Maria Elisabeth Walenkamp, Jean-Sebastien Frenel, Enrico Franceschi, Paul M. Clement, Michael Weller, Iris de Heer, Jim Looman, Jyotirmoy Dey, Scott Krause, Hao Xiong, Peter J Ansell, Sarah Nuyens, Maarten Spruyt, Joana Brilhante, Thierry Gorlia, Vassilis Golfinopoulos

A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209. (Abstract 6021)
Poster Discussion Session: Head and Neck Cancer

Time: Saturday, June 2, 2018, 4:45 – 6 PM

Authors: Martin Schlumberger, Kate Newbold, Baktiar Hasan, Sandrine Marreaud, Samson Assele, Lisa F. Licitra, Patrick Schoffski, Sophie Leboulleux, Laura Locati, Yann Godbert, Vincent Rohmer, Barbara Jarzab, Salvatore Domenico, Oliver Edgar Bechter, Sylvie Zanetta, Jaume Capdevila, Ellen Kapiteijn, Lars Bastholt

EORTC-ESSO 1409 GITCG: A prospective colorectal liver metastasis database with an integrated quality assurance program (CLIMB). (Abstract 3558)
Poster Session: Gastrointestinal Cancer

Time: Sunday, June 3, 2018, 8:00 – 11:30 AM

Authors: Carmela Aves Caballero, Lucia Carrion Alvarez, Henrik Nilsson, Theo Ruers, Perrine Senellart, Michel Rivoire, Stefan Stattner, Florian Primavesi, Roberto Troisi, Thomas Gruenberger, Jan Heil, Andreas Schnitzbauer, Nuh N. Rahbari, Rutger-Jan Swijnenburg, Hassan Zakria Malik, Mladjan Protic, Anouk Neven, Murielle E. Mauer, Graeme John Poston, Serge Evrard